Praful Ravi

3.5k total citations
118 papers, 2.0k citations indexed

About

Praful Ravi is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Praful Ravi has authored 118 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 70 papers in Pulmonary and Respiratory Medicine, 43 papers in Surgery and 34 papers in Oncology. Recurrent topics in Praful Ravi's work include Prostate Cancer Treatment and Research (46 papers), Bladder and Urothelial Cancer Treatments (28 papers) and Prostate Cancer Diagnosis and Treatment (20 papers). Praful Ravi is often cited by papers focused on Prostate Cancer Treatment and Research (46 papers), Bladder and Urothelial Cancer Treatments (28 papers) and Prostate Cancer Diagnosis and Treatment (20 papers). Praful Ravi collaborates with scholars based in United States, United Kingdom and Canada. Praful Ravi's co-authors include Quoc‐Dien Trinh, Maxine Sun, Jesse D. Sammon, Mani Menon, Pierre I. Karakiewicz, James O. Peabody, Shyam Sukumar, Khurshid R. Ghani, Marco Bianchi and Shahrokh F. Shariat and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Praful Ravi

105 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Praful Ravi United States	24	1.0k	680	579	348	191	118	2.0k
Graciela M. Nogueras‐González United States	32	920 0.9×	1.1k 1.6×	1.0k 1.8×	484 1.4×	453 2.4×	135	3.2k
Nora Ruel United States	26	611 0.6×	663 1.0×	514 0.9×	292 0.8×	50 0.3×	104	1.9k
Einar Hannisdal Norway	22	637 0.6×	628 0.9×	1.2k 2.1×	385 1.1×	113 0.6×	64	2.3k
Florian R. Schroeck United States	23	915 0.9×	596 0.9×	348 0.6×	145 0.4×	46 0.2×	92	1.7k
Paul E. Andrews United States	30	1.7k 1.7×	974 1.4×	229 0.4×	662 1.9×	93 0.5×	94	2.6k
Shahrokh F. Shariat Canada	27	1.5k 1.5×	999 1.5×	492 0.8×	635 1.8×	30 0.2×	153	2.6k
Marianne Schmid Germany	34	1.1k 1.1×	977 1.4×	1.1k 2.0×	284 0.8×	47 0.2×	108	3.2k
Antonio Benito Porcaro Italy	23	1.3k 1.2×	624 0.9×	219 0.4×	227 0.7×	38 0.2×	186	2.0k
Rodney Davis United States	33	1.2k 1.2×	1.4k 2.0×	389 0.7×	417 1.2×	40 0.2×	91	2.8k
Gustavo Franco Carvalhal Brazil	20	1.5k 1.5×	530 0.8×	303 0.5×	134 0.4×	61 0.3×	63	2.0k

Countries citing papers authored by Praful Ravi

Since Specialization

Citations

This map shows the geographic impact of Praful Ravi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Praful Ravi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Praful Ravi more than expected).

Fields of papers citing papers by Praful Ravi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Praful Ravi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Praful Ravi. The network helps show where Praful Ravi may publish in the future.

Co-authorship network of co-authors of Praful Ravi

This figure shows the co-authorship network connecting the top 25 collaborators of Praful Ravi. A scholar is included among the top collaborators of Praful Ravi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Praful Ravi. Praful Ravi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ravi, Praful, Wanling Xie, Silke Gillessen, et al.. (2025). Evaluation of clinical risk stratification to determine benefit from long-term versus short-term androgen deprivation in high-risk localized prostate cancer. Prostate Cancer and Prostatic Diseases. 29(1). 202–204. 1 indexed citations

Ravi, Praful, Lucia Kwak, Andrés Acosta, et al.. (2025). Long-term Outcomes and Prognostic Impact of Residual Cancer Burden After Intensified Neoadjuvant Therapy in High-risk Prostate Cancer. European Urology. 87(6). 643–650. 1 indexed citations

Lee, Richard J., Philip J. Saylor, Xin Gao, et al.. (2025). Combination Metastasis-Targeted External Beam Radiation Therapy With 177Lu-PSMA-617 in Patients With Advanced Castration-Resistant Prostate Cancer. Practical Radiation Oncology. 15(6). e597–e605. 4 indexed citations

Ravi, Praful, Katherine K. Perez, Wanling Xie, et al.. (2025). 2416P Prevalence, clonal dynamics and clinical impact of clonal hematopoiesis (CH) in patients (pts) receiving 177Lu-PSMA-617 (LuPSMA) for metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 36. S1228–S1228.

Zarka, Jonathan, Irbaz Bin Riaz, Syed Arsalan Ahmed Naqvi, et al.. (2025). 2403P LuRa: Efficacy and Tolerability of Radium-223 Following [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer. Annals of Oncology. 36. S1223–S1223.

Xie, Wanling, John F. Gallagher, Andrew F. Voter, et al.. (2025). Race and Outcomes to [177Lu]Lu-PSMA-617 in Advanced Prostate Cancer. Cancers. 17(12). 1960–1960. 1 indexed citations

Xie, Wanling, Atish D. Choudhury, Mary‐Ellen Taplin, et al.. (2025). Association between DNA damage repair alterations and outcomes to 177Lu-PSMA-617 in advanced prostate cancer. ESMO Open. 10(2). 104131–104131. 3 indexed citations

Ravi, Praful, Wanling Xie, Marc Buyse, et al.. (2024). Refining Risk Stratification of High-risk and Locoregional Prostate Cancer: A Pooled Analysis of Randomized Trials. European Urology. 87(2). 217–224. 2 indexed citations

Ravi, Praful, Dory Freeman, Jonathan Thomas, et al.. (2024). Comprehensive multiplexed autoantibody profiling of patients with advanced urothelial cancer. Journal for ImmunoTherapy of Cancer. 12(2). e008215–e008215. 2 indexed citations

10.

Choudhury, Atish D., Hyewon Hyun, Emma Kelly, et al.. (2024). Patient outcomes after therapy with ¹⁷⁷Lu-PSMA-617 (LuPSMA) for metastatic castrate-resistant prostate cancer (mCRPC): A tertiary center experience.. Journal of Clinical Oncology. 42(4_suppl). 87–87. 1 indexed citations

11.

Kwak, Lucia, Praful Ravi, John G. Armstrong, et al.. (2024). Prognostic Impact of Prostate-Specific Antigen at 6 Months After Radiotherapy in Localized Prostate Cancer: An Individual Patient Data Analysis of Randomized Trials. Journal of Clinical Oncology. 42(18). 2132–2138. 6 indexed citations

12.

Pan, Elizabeth, Andrew Elliott, Shankar Siva, et al.. (2024). Characterization of FOLH1 Expression in Renal Cell Carcinoma. Cancers. 16(10). 1855–1855. 1 indexed citations

13.

Ravi, Praful, Wanling Xie, Himisha Beltran, et al.. (2024). Combined Fixed-duration Systemic Treatment and Metastasis-directed Radiotherapy for Oligometastatic Hormone-sensitive Prostate Cancer. European Urology Oncology. 8(3). 709–715. 1 indexed citations

14.

McGregor, Bradley A., Guru Sonpavde, Lucia Kwak, et al.. (2023). The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma. Annals of Oncology. 35(1). 91–97. 51 indexed citations

15.

Braga‐Basaria, Milena, Thomas G. Travison, Mary‐Ellen Taplin, et al.. (2023). Gaining metabolic insight in older men undergoing androgen deprivation therapy for prostate cancer (the ADT & Metabolism Study): Protocol of a longitudinal, observational, cohort study. PLoS ONE. 18(2). e0281508–e0281508. 3 indexed citations

16.

Dranitsaris, George, Jonathan Thomas, Catherine Curran, et al.. (2021). An economic analysis comparing health care resource use and cost of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin versus gemcitabine and cisplatin as neoadjuvant therapy for muscle invasive bladder cancer. Urologic Oncology Seminars and Original Investigations. 39(12). 834.e1–834.e7. 7 indexed citations

17.

Ravi, Praful, Grace Shaw, Sarah C. Markt, et al.. (2020). 792P A retrospective review of the survival outcomes of patients with nonseminomatous germ cell tumors (NSGCTs) with and without teratoma in the primary. Annals of Oncology. 31. S603–S603.

18.

Ravi, Praful & Lance C. Pagliaro. (2016). Multimodal Therapy in the Management of Advanced Penile Cancer. Urologic Clinics of North America. 43(4). 469–479. 2 indexed citations

19.

Schmid, Marianne, Praful Ravi, Christian P. Meyer, et al.. (2016). Trends of acute kidney injury after radical or partial nephrectomy for renal cell carcinoma. Urologic Oncology Seminars and Original Investigations. 34(7). 293.e1–293.e10. 41 indexed citations

20.

Roghmann, Florian, Praful Ravi, Julian Hanske, et al.. (2015). Perioperative outcomes after radical cystectomy at NCI-designated centres: Are they any better?. Canadian Urological Association Journal. 9(5-6). 207–207. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact